Share Price and Basic Stock Data
Last Updated: December 15, 2025, 4:31 pm
| PEG Ratio | 0.69 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gennex Laboratories Ltd, operating in the pharmaceuticals sector, has shown a notable growth trajectory in its revenue streams. The company reported sales of ₹66 Cr for FY 2023, a significant increase from ₹61 Cr in FY 2022. In the current fiscal year, revenues are projected to rise sharply, with Q1 FY 2025 showing sales of ₹35.52 Cr. The trend appears robust, with quarterly sales fluctuating but generally trending upwards, peaking at ₹40.33 Cr in March 2025. This upward momentum indicates a solid demand for Gennex’s products, which is crucial in the competitive pharmaceutical landscape. However, the volatility in quarterly sales, particularly the dip to ₹14.51 Cr in June 2022, raises questions about seasonality or market challenges that investors should watch closely.
Profitability and Efficiency Metrics
Profitability metrics for Gennex Laboratories reflect a positive trajectory, albeit with some fluctuations. The company’s net profit stood at ₹19 Cr in FY 2025, which is a significant leap from ₹5 Cr in FY 2023. Operating Profit Margin (OPM) has seen a remarkable improvement, peaking at 31.74% in September 2023, but it later declined to 14.83% by June 2025. This inconsistency suggests that while Gennex is capable of high margins, maintaining them could be a challenge. The Return on Equity (ROE) of 10.2% and Return on Capital Employed (ROCE) of 13.0% indicate that the company is generating decent returns on investors’ capital. However, the Cash Conversion Cycle (CCC) of 123 days indicates a need for efficiency improvements in inventory and receivables management.
Balance Sheet Strength and Financial Ratios
Gennex’s balance sheet exhibits a mix of strengths and areas that require attention. The company reported total borrowings of ₹88 Cr, which, while manageable given the ₹314 Cr market capitalization, suggests a reliance on debt that investors should monitor. With reserves standing at ₹189 Cr, the company appears to have a solid foundation for future growth. The Interest Coverage Ratio (ICR) of 7.52x indicates that Gennex can comfortably cover its interest obligations, showcasing financial prudence. However, the low Debt to Equity ratio of 0.05x indicates that the company is not heavily leveraged, which is a positive sign for risk-averse investors. Despite these strengths, the company’s cash flow management needs scrutiny, especially given the fluctuating operating profit margins and the CCC figure.
Shareholding Pattern and Investor Confidence
The shareholding structure of Gennex Laboratories reveals an interesting dynamic, with public shareholders holding 76.38% of the company. Promoter holding stands at 23.62%, which has seen some fluctuations but remains relatively stable. This distribution suggests a strong retail investor base, which can be a positive indicator of confidence in the company’s future prospects. The number of shareholders has grown from 58,248 in December 2022 to 90,320 in September 2025, reflecting increasing interest from retail investors. However, the absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) could imply that institutional confidence is still developing. This could affect liquidity and price stability in the stock, especially in volatile market conditions.
Outlook, Risks, and Final Insight
Looking ahead, Gennex Laboratories presents a mixed bag of opportunities and challenges. The significant revenue growth indicates a potential for sustained expansion, but the company’s ability to maintain profitability amidst fluctuating operating margins is a concern. Risks include reliance on a public shareholder base, which could lead to volatility if sentiment shifts. Additionally, the high Cash Conversion Cycle may signal operational inefficiencies that need addressing. Investors should consider these factors when evaluating Gennex’s stock. While the fundamentals appear strong, the company’s performance in managing costs and maintaining investor confidence will be crucial for long-term success. A prudent approach would involve close monitoring of quarterly results and operational efficiencies as Gennex navigates the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 237/84.3 | 32.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,256 Cr. | 391 | 479/192 | 88.1 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.2 Cr. | 43.4 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.1 Cr. | 30.8 | 31.0/17.0 | 107 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,430.04 Cr | 1,157.00 | 52.75 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14.51 | 19.62 | 14.63 | 20.80 | 16.52 | 18.18 | 21.39 | 35.52 | 28.32 | 33.38 | 40.01 | 40.33 | 34.18 |
| Expenses | 13.06 | 17.76 | 12.81 | 17.28 | 11.42 | 12.41 | 16.59 | 29.26 | 24.10 | 25.92 | 32.86 | 38.31 | 29.11 |
| Operating Profit | 1.45 | 1.86 | 1.82 | 3.52 | 5.10 | 5.77 | 4.80 | 6.26 | 4.22 | 7.46 | 7.15 | 2.02 | 5.07 |
| OPM % | 9.99% | 9.48% | 12.44% | 16.92% | 30.87% | 31.74% | 22.44% | 17.62% | 14.90% | 22.35% | 17.87% | 5.01% | 14.83% |
| Other Income | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 2.47 | -0.00 | -0.00 | 3.68 | 2.28 |
| Interest | 0.26 | 0.10 | 0.19 | 0.63 | 0.73 | 0.78 | 0.83 | 0.73 | 0.73 | 0.22 | 0.84 | 1.20 | 0.98 |
| Depreciation | 0.18 | 0.36 | 0.18 | 0.37 | 0.65 | 1.03 | 0.45 | 0.23 | 0.45 | 1.11 | 0.50 | 0.54 | 0.50 |
| Profit before tax | 1.01 | 1.40 | 1.45 | 2.52 | 3.72 | 3.96 | 3.52 | 5.30 | 5.51 | 6.13 | 5.81 | 3.96 | 5.87 |
| Tax % | 24.75% | 25.00% | 24.83% | 19.05% | 23.39% | 22.47% | 21.31% | 15.28% | 15.43% | 12.23% | 12.91% | 22.22% | 14.48% |
| Net Profit | 0.75 | 1.05 | 1.08 | 2.04 | 2.85 | 3.07 | 2.76 | 4.50 | 4.66 | 5.38 | 5.06 | 3.07 | 5.01 |
| EPS in Rs | 0.04 | 0.06 | 0.07 | 0.12 | 0.16 | 0.17 | 0.15 | 0.20 | 0.19 | 0.21 | 0.20 | 0.10 | 0.20 |
Last Updated: August 19, 2025, 6:10 pm
Below is a detailed analysis of the quarterly data for Gennex Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 34.18 Cr.. The value appears to be declining and may need further review. It has decreased from 40.33 Cr. (Mar 2025) to 34.18 Cr., marking a decrease of 6.15 Cr..
- For Expenses, as of Jun 2025, the value is 29.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.31 Cr. (Mar 2025) to 29.11 Cr., marking a decrease of 9.20 Cr..
- For Operating Profit, as of Jun 2025, the value is 5.07 Cr.. The value appears strong and on an upward trend. It has increased from 2.02 Cr. (Mar 2025) to 5.07 Cr., marking an increase of 3.05 Cr..
- For OPM %, as of Jun 2025, the value is 14.83%. The value appears strong and on an upward trend. It has increased from 5.01% (Mar 2025) to 14.83%, marking an increase of 9.82%.
- For Other Income, as of Jun 2025, the value is 2.28 Cr.. The value appears to be declining and may need further review. It has decreased from 3.68 Cr. (Mar 2025) to 2.28 Cr., marking a decrease of 1.40 Cr..
- For Interest, as of Jun 2025, the value is 0.98 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.20 Cr. (Mar 2025) to 0.98 Cr., marking a decrease of 0.22 Cr..
- For Depreciation, as of Jun 2025, the value is 0.50 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.54 Cr. (Mar 2025) to 0.50 Cr., marking a decrease of 0.04 Cr..
- For Profit before tax, as of Jun 2025, the value is 5.87 Cr.. The value appears strong and on an upward trend. It has increased from 3.96 Cr. (Mar 2025) to 5.87 Cr., marking an increase of 1.91 Cr..
- For Tax %, as of Jun 2025, the value is 14.48%. The value appears to be improving (decreasing) as expected. It has decreased from 22.22% (Mar 2025) to 14.48%, marking a decrease of 7.74%.
- For Net Profit, as of Jun 2025, the value is 5.01 Cr.. The value appears strong and on an upward trend. It has increased from 3.07 Cr. (Mar 2025) to 5.01 Cr., marking an increase of 1.94 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.20. The value appears strong and on an upward trend. It has increased from 0.10 (Mar 2025) to 0.20, marking an increase of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:40 am
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 44 | 56 | 56 | 60 | 61 | 66 | 87 | 138 | 152 |
| Expenses | 37 | 42 | 52 | 52 | 53 | 56 | 61 | 70 | 121 | 132 |
| Operating Profit | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 17 | 17 | 20 |
| OPM % | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 20% | 12% | 13% |
| Other Income | 0 | 1 | 1 | 1 | 0 | 1 | 4 | 5 | 10 | 8 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 16 | 21 | 22 |
| Tax % | 13% | 42% | 26% | 27% | 20% | 23% | 23% | 20% | 15% | |
| Net Profit | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 13 | 18 | 19 |
| EPS in Rs | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.28 | 0.58 | 0.80 | 0.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -66.67% | 100.00% | 0.00% | 100.00% | 0.00% | 25.00% | 160.00% | 38.46% |
| Change in YoY Net Profit Growth (%) | 0.00% | 166.67% | -100.00% | 100.00% | -100.00% | 25.00% | 135.00% | -121.54% |
Gennex Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 31% |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 56% |
| 3 Years: | 61% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 20% |
| 3 Years: | 17% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 9% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:56 am
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 | 23 | 24 |
| Reserves | 18 | 19 | 21 | 23 | 27 | 31 | 62 | 148 | 164 | 189 |
| Borrowings | 4 | 2 | 5 | 5 | 7 | 10 | 1 | 6 | 10 | 88 |
| Other Liabilities | 14 | 16 | 13 | 16 | 12 | 14 | 51 | 54 | 59 | 55 |
| Total Liabilities | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 357 |
| Fixed Assets | 16 | 16 | 16 | 15 | 14 | 14 | 74 | 56 | 60 | 76 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 0 |
| Investments | 7 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Other Assets | 26 | 28 | 29 | 35 | 38 | 48 | 59 | 172 | 191 | 281 |
| Total Assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 357 |
Below is a detailed analysis of the balance sheet data for Gennex Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 189.00 Cr.. The value appears strong and on an upward trend. It has increased from 164.00 Cr. (Mar 2025) to 189.00 Cr., marking an increase of 25.00 Cr..
- For Borrowings, as of Sep 2025, the value is 88.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 10.00 Cr. (Mar 2025) to 88.00 Cr., marking an increase of 78.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 55.00 Cr.. The value appears to be improving (decreasing). It has decreased from 59.00 Cr. (Mar 2025) to 55.00 Cr., marking a decrease of 4.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 357.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 256.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 101.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 76.00 Cr.. The value appears strong and on an upward trend. It has increased from 60.00 Cr. (Mar 2025) to 76.00 Cr., marking an increase of 16.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 281.00 Cr.. The value appears strong and on an upward trend. It has increased from 191.00 Cr. (Mar 2025) to 281.00 Cr., marking an increase of 90.00 Cr..
- For Total Assets, as of Sep 2025, the value is 357.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 101.00 Cr..
Notably, the Reserves (189.00 Cr.) exceed the Borrowings (88.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | 0.00 | -1.00 | -2.00 | 0.00 | -5.00 | 4.00 | 11.00 | 7.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 87 | 68 | 41 | 55 | 67 | 52 | 75 | 37 |
| Inventory Days | 43 | 31 | 57 | 78 | 50 | 72 | 139 | 184 | 135 |
| Days Payable | 139 | 161 | 88 | 86 | 59 | 72 | 63 | 111 | 49 |
| Cash Conversion Cycle | -7 | -43 | 38 | 34 | 46 | 67 | 129 | 148 | 123 |
| Working Capital Days | 74 | 75 | 56 | 87 | 108 | 87 | 23 | 255 | 214 |
| ROCE % | 6% | 11% | 8% | 14% | 12% | 11% | 14% | 12% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.80 | 0.66 | 0.42 | 0.33 | 0.32 |
| Diluted EPS (Rs.) | 0.78 | 0.66 | 0.42 | 0.33 | 0.32 |
| Cash EPS (Rs.) | 0.88 | 0.68 | 0.32 | 0.37 | 0.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 8.21 | 7.49 | 4.46 | 3.46 | 3.14 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 8.21 | 7.49 | 4.46 | 3.46 | 3.14 |
| Revenue From Operations / Share (Rs.) | 6.06 | 3.81 | 3.64 | 4.84 | 4.72 |
| PBDIT / Share (Rs.) | 1.19 | 0.96 | 0.47 | 0.53 | 0.55 |
| PBIT / Share (Rs.) | 1.11 | 0.86 | 0.42 | 0.47 | 0.48 |
| PBT / Share (Rs.) | 0.94 | 0.72 | 0.35 | 0.40 | 0.40 |
| Net Profit / Share (Rs.) | 0.79 | 0.57 | 0.27 | 0.31 | 0.31 |
| NP After MI And SOA / Share (Rs.) | 0.79 | 0.57 | 0.27 | 0.31 | 0.31 |
| PBDIT Margin (%) | 19.68 | 25.29 | 13.17 | 11.04 | 11.83 |
| PBIT Margin (%) | 18.24 | 22.56 | 11.77 | 9.75 | 10.35 |
| PBT Margin (%) | 15.51 | 19.01 | 9.71 | 8.32 | 8.48 |
| Net Profit Margin (%) | 13.14 | 15.19 | 7.50 | 6.40 | 6.76 |
| NP After MI And SOA Margin (%) | 13.14 | 15.19 | 7.50 | 6.40 | 6.76 |
| Return on Networth / Equity (%) | 9.70 | 7.73 | 6.12 | 8.95 | 10.16 |
| Return on Capital Employeed (%) | 11.89 | 10.31 | 7.51 | 13.62 | 15.49 |
| Return On Assets (%) | 7.07 | 5.72 | 3.71 | 5.76 | 6.85 |
| Total Debt / Equity (X) | 0.05 | 0.03 | 0.01 | 0.23 | 0.18 |
| Asset Turnover Ratio (%) | 0.56 | 0.47 | 0.65 | 0.96 | 1.03 |
| Current Ratio (X) | 4.07 | 4.01 | 1.65 | 1.95 | 1.98 |
| Quick Ratio (X) | 3.26 | 3.39 | 1.12 | 1.63 | 1.71 |
| Inventory Turnover Ratio (X) | 4.51 | 2.83 | 4.00 | 6.27 | 5.49 |
| Interest Coverage Ratio (X) | 7.52 | 7.13 | 6.39 | 7.70 | 9.49 |
| Interest Coverage Ratio (Post Tax) (X) | 6.06 | 5.28 | 4.63 | 5.47 | 6.93 |
| Enterprise Value (Cr.) | 236.62 | 310.20 | 93.24 | 97.07 | 55.76 |
| EV / Net Operating Revenue (X) | 1.72 | 3.58 | 1.42 | 1.59 | 0.93 |
| EV / EBITDA (X) | 8.72 | 14.14 | 10.78 | 14.36 | 7.90 |
| MarketCap / Net Operating Revenue (X) | 1.99 | 4.14 | 1.54 | 1.56 | 0.82 |
| Price / BV (X) | 1.47 | 2.11 | 1.26 | 2.17 | 1.25 |
| Price / Net Operating Revenue (X) | 1.99 | 4.14 | 1.54 | 1.56 | 0.82 |
| EarningsYield | 0.06 | 0.03 | 0.04 | 0.04 | 0.08 |
After reviewing the key financial ratios for Gennex Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.80, marking an increase of 0.14.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.78, marking an increase of 0.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 3. It has increased from 0.68 (Mar 24) to 0.88, marking an increase of 0.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.21. It has increased from 7.49 (Mar 24) to 8.21, marking an increase of 0.72.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.21. It has increased from 7.49 (Mar 24) to 8.21, marking an increase of 0.72.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.06. It has increased from 3.81 (Mar 24) to 6.06, marking an increase of 2.25.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 2. It has increased from 0.96 (Mar 24) to 1.19, marking an increase of 0.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.86 (Mar 24) to 1.11, marking an increase of 0.25.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.94. This value is within the healthy range. It has increased from 0.72 (Mar 24) to 0.94, marking an increase of 0.22.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 2. It has increased from 0.57 (Mar 24) to 0.79, marking an increase of 0.22.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 2. It has increased from 0.57 (Mar 24) to 0.79, marking an increase of 0.22.
- For PBDIT Margin (%), as of Mar 25, the value is 19.68. This value is within the healthy range. It has decreased from 25.29 (Mar 24) to 19.68, marking a decrease of 5.61.
- For PBIT Margin (%), as of Mar 25, the value is 18.24. This value is within the healthy range. It has decreased from 22.56 (Mar 24) to 18.24, marking a decrease of 4.32.
- For PBT Margin (%), as of Mar 25, the value is 15.51. This value is within the healthy range. It has decreased from 19.01 (Mar 24) to 15.51, marking a decrease of 3.50.
- For Net Profit Margin (%), as of Mar 25, the value is 13.14. This value exceeds the healthy maximum of 10. It has decreased from 15.19 (Mar 24) to 13.14, marking a decrease of 2.05.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.14. This value is within the healthy range. It has decreased from 15.19 (Mar 24) to 13.14, marking a decrease of 2.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.70. This value is below the healthy minimum of 15. It has increased from 7.73 (Mar 24) to 9.70, marking an increase of 1.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.89. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 11.89, marking an increase of 1.58.
- For Return On Assets (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has increased from 5.72 (Mar 24) to 7.07, marking an increase of 1.35.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.05. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has increased from 0.47 (Mar 24) to 0.56, marking an increase of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 4.07, marking an increase of 0.06.
- For Quick Ratio (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 2. It has decreased from 3.39 (Mar 24) to 3.26, marking a decrease of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.51. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 4.51, marking an increase of 1.68.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.52. This value is within the healthy range. It has increased from 7.13 (Mar 24) to 7.52, marking an increase of 0.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.06. This value is within the healthy range. It has increased from 5.28 (Mar 24) to 6.06, marking an increase of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 236.62. It has decreased from 310.20 (Mar 24) to 236.62, marking a decrease of 73.58.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has decreased from 3.58 (Mar 24) to 1.72, marking a decrease of 1.86.
- For EV / EBITDA (X), as of Mar 25, the value is 8.72. This value is within the healthy range. It has decreased from 14.14 (Mar 24) to 8.72, marking a decrease of 5.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has decreased from 4.14 (Mar 24) to 1.99, marking a decrease of 2.15.
- For Price / BV (X), as of Mar 25, the value is 1.47. This value is within the healthy range. It has decreased from 2.11 (Mar 24) to 1.47, marking a decrease of 0.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has decreased from 4.14 (Mar 24) to 1.99, marking a decrease of 2.15.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gennex Laboratories Ltd:
- Net Profit Margin: 13.14%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.89% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.7% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.06
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.26
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.9 (Industry average Stock P/E: 52.75)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.14%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sy. No.133, Sangareddy Dist. Telangana 502325 | info@gennexlab.com http://www.gennexlab.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arihant Baid | Managing Director |
| Dr. A R R Pantulu | Non Executive Director |
| Mr. Sandeep Kumar Daga | Non Executive Director |
| Mr. A S Nageswar Rao | Independent Director |
| Mr. Dilip Raj Singhvi | Independent Director |
| Ms. Shilpa Bung | Independent Woman Director |
FAQ
What is the intrinsic value of Gennex Laboratories Ltd?
Gennex Laboratories Ltd's intrinsic value (as of 15 December 2025) is 13.83 which is 7.21% higher the current market price of 12.90, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 314 Cr. market cap, FY2025-2026 high/low of 19.0/10.8, reserves of ₹189 Cr, and liabilities of 357 Cr.
What is the Market Cap of Gennex Laboratories Ltd?
The Market Cap of Gennex Laboratories Ltd is 314 Cr..
What is the current Stock Price of Gennex Laboratories Ltd as on 15 December 2025?
The current stock price of Gennex Laboratories Ltd as on 15 December 2025 is 12.9.
What is the High / Low of Gennex Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gennex Laboratories Ltd stocks is 19.0/10.8.
What is the Stock P/E of Gennex Laboratories Ltd?
The Stock P/E of Gennex Laboratories Ltd is 18.9.
What is the Book Value of Gennex Laboratories Ltd?
The Book Value of Gennex Laboratories Ltd is 8.79.
What is the Dividend Yield of Gennex Laboratories Ltd?
The Dividend Yield of Gennex Laboratories Ltd is 0.00 %.
What is the ROCE of Gennex Laboratories Ltd?
The ROCE of Gennex Laboratories Ltd is 13.0 %.
What is the ROE of Gennex Laboratories Ltd?
The ROE of Gennex Laboratories Ltd is 10.2 %.
What is the Face Value of Gennex Laboratories Ltd?
The Face Value of Gennex Laboratories Ltd is 1.00.